Bristol Myers pays SystImmune $800M and adds to pharma’s ‘ADC’ deal spree

Bristol Myers pays SystImmune $800M and adds to pharma’s ‘ADC’ deal spree

Submitted by admin on December 12, 2023 - 9:58am
Source: 
BioPharma Dive
News Tags: 
Bristol Myers Squibb
SystImmune
antibody-drug conjugate
cancer
Headline: 
Bristol Myers pays SystImmune $800M and adds to pharma’s ‘ADC’ deal spree
snippet: 

Bristol Myers Squibb is paying biotechnology startup SystImmune $800 million for rights to an experimental cancer treatment, adding to a recent surge in pharmaceutical dealmaking for drugs of its kind.

Do Not Allow Advertisers to Use My Personal information